Welcome to our dedicated page for PRECISION PEPTID news (Ticker: PNGAF), a resource for investors and traders seeking the latest updates and insights on PRECISION PEPTID stock.
The Precision Peptide Company reports developments around advanced peptide formulations and delivery systems for the wellness market. Recurring updates include the Amino Innovations platform, needle-free transdermal peptide patches, the BPC-157 patch, the Immune Defense Patch formulated with Thymosin Alpha-1, and broader work on oral and transdermal delivery technology.
Company news also covers capital and governance actions such as warrant exercises, restricted share units, stock options, debt settlement, material agreements, and commentary on the evolving U.S. regulatory framework for peptide substances. The company describes products manufactured in an approved U.S. facility and distributed across North America.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) reported independent lab data for its lead BPC-157 transdermal patch. Miraxis Labs confirmed 95.5% chromatographic purity and a 2.02 mg measured dose per patch using UHPLC-DAD, exceeding the ≥95% industry benchmark and supporting progression toward commercial launch, subject to further testing, scale-up and regulatory considerations.
The Precision Peptide Company (OTCQB: PNGAF) announced that Justin Kirkland, Co-Founder and Chief Scientific Officer of subsidiary Amino Innovations, will appear on The Human Upgrade with Dave Asprey. The episode, focused on peptide-based wellness and delivery formats, is scheduled for June 4, 2026.
The feature highlights Amino Innovations' needle-free BPC-157 transdermal patch development, the ongoing research collaboration with the University of Alberta's Drug Development and Innovation Centre, and a broader U.S. regulatory shift in favor of peptide therapies.
The Precision Peptide Company (CSE:BPC, OTCQB:PNGAF) entered an Exclusive Strategic Marketing Agreement with Mixed Martial Arts Group Limited on May 8, 2026. MMA will market BPC’s peptide products to its large global combat sports ecosystem.
MMA has over 5 million social followers, about 530,000 user profiles, more than 75,000 active students and 800+ verified gyms. Net revenue from MMA-sourced sales is shared 50%/50% in year one, then 75% to BPC and 25% to MMA thereafter. Products will be manufactured in the U.S. and comply with applicable FDA and other U.S. regulatory standards.
The Precision Peptide Company (OTCQB: PNGAF) reports progress on a needle-free BPC-157 transdermal patch, now in active testing with near-term results expected. Subject to satisfactory tests, the company plans to advance the patch toward commercial release as part of a multi-product transdermal platform under Amino Innovations.
The patch is designed for sustained skin delivery to lower needle aversion barriers. A second TA-1 immune patch is in development. Testing is supported by a research services agreement with the University of Alberta. The company cautions there is no assurance testing or commercialization will succeed or produce revenue.
The Precision Peptide Company (OTCQB: PNGAF) received approximately C$1.3 million from the exercise of outstanding warrants on May 5, 2026.
Proceeds will strengthen the balance sheet and fund development and expansion of the Amino Innovations platform, including product rollout, delivery technology advancement, and North American distribution growth.
The Precision Peptide Company (OTCQB: PNGAF) granted 600,000 RSUs (300,000 vesting 15 Jun 2026; 300,000 vesting 15 Jan 2027), issued 1,100,000 stock options at $0.50 exercisable for three years, and settled $125,000 of indebtedness to the CEO by issuing 300,000 common shares at a deemed $0.42 per share subject to a four-month hold. The debt settlement is a related-party transaction relying on MI 61-101 exemptions.
The Precision Peptide Company (OTCQB: PNGAF) entered a strategic product marketing agreement with UK agency Raw Creation on April 20, 2026. The six-month engagement runs to October 20, 2026, for a one-time setup fee of CAD$9,000 plus a prepaid retainer of CAD$76,500 (total CAD$85,500), converting thereafter to a rolling monthly retainer of CAD$15,000. Services include social media management, creative/video production, editorial/press and paid advertising. The agreement is arm’s-length and subject to Canadian Securities Exchange approval.
The Precision Peptide Company (OTCQB: PNGAF) applauded recent FDA actions on April 16, 2026, that remove several peptides from Category 2 and refer them for further review by the Pharmacy Compounding Advisory Committee, calling the move a step toward clearer, science‑based regulation.
The company also granted 800,000 stock options to consultants at an exercise price of $0.50, exercisable over one to three years with a four‑month hold period.
The Precision Peptide Company (OTCQB: PNGAF) entered two investor relations and consulting agreements in April 2026. The company contracted Think Ink for 12 months (Apr 16, 2026–Apr 15, 2027) with an up-front marketing budget of USD $250,000.
It also retained Ouimet for consulting (Apr 21, 2026–May 21, 2026) for a USD $65,000 cash fee. Both agreements are subject to Canadian Securities Exchange approval and parties are described as arm’s-length.
The Precision Peptide Company (OTCQB: PNGAF) launched a new corporate website on April 7, 2026 to provide regular updates on company developments.
The company commented on evolving U.S. policy signals from Health and Human Services leadership that could ease access to certain peptides and allow compounding pharmacies to make products currently restricted by the FDA. The company said it is exploring potential U.S. opportunities while emphasizing compliance, quality, and scale and noted no decisions have been made.